Abstract
Background Low-intensity repetitive transcranial magnetic stimulation (rTMS), delivered as a daily intermittent theta burst stimulation (iTBS) for 4 consecutive weeks, increases the number of new oligodendrocytes in the adult mouse brain. rTMS holds potential as a remyelinating intervention for people with MS.
Objective Primarily to determine the safety and tolerability of our rTMS protocol in people with MS. Secondary objectives included feasibility, blinding, and an exploration of changes in magnetic resonance imaging (MRI) metrics, patient reported outcome measures (PROMs) and cognitive or motor performance.
Methods A randomised (2:1), placebo controlled, single blind, parallel group, phase 1 trial of 20 rTMS sessions (600 iTBS pulses per hemisphere; 25% maximum stimulator output), delivered over 4-5 weeks, with the coil positioned at 90° (n=7, ‘sham’) or 0° (n=13, active rTMS).
Results Five adverse events (AEs) including one serious AE reported. None were related to treatment. Protocol compliance was high (85%) and blinding successful. Within participant MRI metrics, PROMs and cognitive or motor performance were unchanged over time.
Conclusion 20 sessions of rTMS is safe and well tolerated in a small group of people with MS. The study protocol and procedures are feasible. Improvement of sham is warranted before further investigating safety and efficacy.
Trial registration Australian New Zealand Clinical Trials Registry (ACTRN12619001196134). https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378010&isReview=true
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ACTRN12619001196134
Clinical Protocols
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06526-z
Funding Statement
The study was funded by the Royal Hobart Hospital Research Foundation (C0026309), the Medical Research Future Fund (EPCD000008), the Medical Protection Society of Tasmania (MPST), the Menzies Institute for Medical Research and the Irene Phelps Charitable Trust. KMY, KM and BVT received fellowship support from MS Research Australia (17-0223, 19-0696 and 21-3-023) and / or the National Health and Medical Research Council (2021/GNT2009389).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Human Research Ethics Committee of the University of Tasmania gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
